Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Detox-B adjuvant
- Development stage
- Preclinical
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular, Subcutaneous, Intradermal, Intratumoral
01
Overview
Detox-B adjuvant is a cancer vaccine adjuvant composed of an oil droplet emulsion containing monophosphoryl lipid A and mycobacterial cell wall skeleton. It acts as a non-specific immunostimulant, enhancing the host immune response to certain cancer vaccines by stimulating innate immunity and promoting antigen presentation. Its primary use is as an immunological booster in experimental or investigational cancer vaccine formulations[1][2].
- Brand names
- Enhanzyn
- Other names
- Detox-BDetox-B adjuvant
02
Targets
TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on Detox-B adjuvant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Detox-B adjuvant.